Our Spine Intervention Portfolio consists of targeted solutions offering spinal fusion, adhesion control and prevention, and treating osteoarthritis.
Leader Biomedical’s Hyalosyn™ Gel with Hyaluronic Acid (HA) injections supplement the natural human HA found in the synovial joints. Hyalosyn™ Gel is a 1% sodium hyaluronate viscoelastic sterile solution in a pre-filled syringe for improved joint mobility with three to five injections (one per week). Hyalosyn™ Gel relieves joint pain caused by osteoarthritis for long-term effect on improved joint mobility, suitable for intra-articular injection into all synovial joints. Hyalosyn™ Gel is manufactured by unique biotechnological synthetic fermentation, ensuring a high purity with no microbiological residues and boosts an extensive clinical history of more than 10 years with proven pain relief and treatment of degenerative joints.
Adcon® Gel is a biocompatible resorbable gel that provides a barrier to inter-tissue adhesions and inhibits fibroblast migration. The result is improved patient rehabilitation, reduced recurrent pain, and decreased number re-operations as a result of such adhesions. Adcon® Gel has been used and proven in over 300,000 cases and in more than 10 clinical studies since 1996
Leader Biomedical’s Intervention Spine Portfolio is complemented with eTiss®allografts processed and cleaned with our proprietary eCOO® Technology utilising super critical carbon dioxide (scCO2), and the OssGro® and Ossfinity® line of synthetic grafts produced with MBCP™ Technology, a proprietary method composed of 60% HA and 40% βTCP.